Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents

Pitt T L; Sparrow M; Warner M; Stefanidou M
September 2003
Thorax;Sep2003, Vol. 58 Issue 9, p794
Academic Journal
BACKGROUND: Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown. METHODS: The susceptibility of 417 CF patient isolates of P aeruginosa from 17 hospitals to six commonly prescribed antibiotics were examined. Isolates were tested by an agar break point dilution method and E-tests according to British Society of Antimicrobial Chemotherapy guidelines. Genotyping of isolates was performed by XbaI DNA macrorestriction and pulsed field gel electrophoresis. RESULTS: 38% of isolates were susceptible to all of the agents tested; almost half were resistant to gentamicin compared with ceftazidime (39%), piperacillin (32%), ciprofloxacin (30%), tobramycin (10%), and colistin (3%). Approximately 40% were resistant to two or more compounds with ceftazidime in combination with gentamicin, piperacillin or ciprofloxacin being the most common cross resistances. Resistance rates were generally similar to those reported recently from the USA and Germany. A selection of resistant isolates proved to be predominantly genotypically distinct by XbaI DNA macrorestriction but six pairs from three centres had similar genotypes. CONCLUSIONS: The level of resistance to front line antipseudomonal agents, with the exception of colistin, is disturbingly high. The prudent use of antimicrobial drugs and closer monitoring of accumulation of resistant strain populations should be actively considered.


Related Articles

  • Tobramycin.  // Reactions Weekly;3/31/2007, Issue 1145, p17 

    The article presents the case report of a boy with cystic fibrosis who developed recurrent eosinophilia and branchospasm after administration of tobramycin. He was given tobramycin for wheezing and deep throat culture revealed Pseudomonas aeruginosa. When the drug was discontinued, his symptoms...

  • Mechanisms of cystic fibrosis.  // Thorax;Dec2013 Supplement, Vol. 68 Issue S3, pA53 

    The article presents abstracts on topics related to cystic fibrosis (CF) mechanisms including T-helper cell response against Pseudomonas aeruginosa in cystic fibrosis patients, functional variant of protein Elafin with anti-inflammatory activity, and respiratory viruses' effect on CF patients.

  • Cross infection of cystic fibrosis patients with Pseudomonas aeruginosa. Pitt, T.L. // Thorax;Nov2002, Vol. 57 Issue 11, p921 

    Editorial. Focuses on cross infection of cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Mortality rate of CF patients; Choice of antimicrobial compounds; Drug resistance.

  • P. aeruginosa identified in patients with cystic fibrosis. DeNyse, Ashley; Henry, Jennifer // Infectious Disease News;Dec2010, Vol. 23 Issue 12, p24 

    The article reports on a study which identified Pseudomonas aeruginosa in patients with cystic fibrosis in Canada and Great Britain.

  • Cystic Fibrosis.  // Current Medical Literature: Respiratory Medicine;2010, Vol. 24 Issue 3, p67 

    The article discusses studies on cystic fibrosis. L. Saiman et al examined the effect of azithromycin on pulmonary function in cystic fibrosis (CF) patients uninfected with Pseudomonas aeruginosa. The editor notes that the benefits of azithromycin on the quality of life of CF patients were...

  • Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Alcalá-Franco, Beatriz; Montanari, Sara; Cigana, Cristina; Bertoni, Giovanni; Oliver, Antonio; Bragonzi, Alessandra // Journal of Antimicrobial Chemotherapy (JAC);Apr2012, Vol. 67 Issue 4, p962 

    Objectives Hypermutable strains of Pseudomonas aeruginosa frequently emerge during chronic airways infection in cystic fibrosis (CF) patients. While the increased accumulation of mutations by hypermutable strains determines a biological cost for the colonization of secondary environments, the...

  • How to use: bacterial cultures in diagnosing lower respiratory tract infections in cystic fibrosis. Ahmed, Bushra; Bush, Andrew; Davies, Jane C. // Archives of Disease in Childhood -- Education & Practice Edition;Oct2014, Vol. 99 Issue 5, p181 

    Respiratory infections are the leading cause of morbidity and mortality in cystic fibrosis. Certain bacteria, such as Pseudomonas aeruginosa, are associated with a worse clinical outcome than others, but can be completely eradicated if identified and treated early. The diagnosis of lower...

  • Molecular Epidemiology of Chronic Pseudomonas aeruginosa Airway Infections in Cystic Fibrosis. Cramer, Nina; Wiehlmann, Lutz; Ciofu, Oana; Tamm, Stephanie; Høiby, Niels; Tümmler, Burkhard // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Background/Methods: The molecular epidemiology of the chronic airway infections with Pseudomonas aeruginosa in individuals with cystic fibrosis (CF) was investigated by cross-sectional analysis of bacterial isolates from 51 CF centers and by longitudinal analysis of serial isolates which had...

  • Intrinsic and Environmental Mutagenesis Drive Diversification and Persistence of Pseudomonas aeruginosa in Chronic Lung Infections. Rodríguez-Rojas, Alexandro; Oliver, Antonio; Blázquez1, Jesús // Journal of Infectious Diseases;1/1/2012, Vol. 205 Issue 1, p121 

    Pseudomonas aeruginosa is a versatile opportunistic pathogen causing a wide variety of hospital-acquired acute infections in immunocompromised patients as well as chronic respiratory infections in patients suffering from cystic fibrosis or other chronic respiratory diseases. Several traits...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics